Atrial Fibrillation – New Frontiers in Anticoagulation

Author(s): Ranji Thomas, Pierre Le Page, Andrew R.J. Mitchell

Journal Name: Cardiovascular & Hematological Disorders-Drug Targets
Formerly Current Drug Targets - Cardiovascular & Hematological Disorders

Volume 14 , Issue 1 , 2014

Become EABM
Become Reviewer
Call for Editor


Stroke is the most feared complication of atrial fibrillation but for over fifty years there has been no simple, effective preventative alternative to warfarin. The development of new risk algorithms such as CHADSVASC has resulted in more patients being recommended anticoagulation therapy. Fixed dose oral anticoagulation is a landmark in drug development for atrial fibrillation. The differences between the drugs are discussed and the trial data examined. As we enter this new frontier of therapy, there is no doubt that these drugs will transform the delivery of anticoagulation for patients with atrial fibrillation.

Keywords: Atrial fibrillation, apixaban, dabigatran, direct thrombin inhibitors, edoxaban, factor Xa, thromboembolism, warfarin, rivoroxaban.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 23 July, 2014
Page: [45 - 49]
Pages: 5
DOI: 10.2174/1871529X1401140724094846

Article Metrics

PDF: 38